EUVIMEDEUVIMED entdecken
Open Access

Clinical Variant Reclassification in Hereditary Disease Genetic Testing

Yuya Kobayashi, Elaine Chen, Flavia M Facio, Hillery Metz, Sarah R Poll, Dan Swartzlander, Britt Johnson, Swaroop Aradhya

JAMA Network Open · 06.11.2024 · 7 (11) · e2444526

DOI: 10.1001/jamanetworkopen.2024.44526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 06.11.2024. Verfasst von Yuya Kobayashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Labcorp Genetics Inc (formerly Invitae Corporation), San Francisco, California. Hauptthemen laut MEDLINE: Genetic Testing, Genetic Diseases, Inborn. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Because accurate and consistent classification of DNA sequence variants is fundamental to germline genetic testing, understanding patterns of initial variant classification (VC) and subsequent reclassification from large-scale, empirical data can help improve VC methods, promote equity among race, ethnicity, and ancestry (REA) groups, and provide insights to inform clinical practice.

Objectives

To measure the degree to which initial VCs met certainty thresholds set by professional guidelines and quantify the rates of, the factors associated with, and the impact of reclassification among more than 2 million variants. Design, Setting, and Participants This cohort study used clinical multigene panel and exome sequencing data from diagnostic testing for hereditary disorders, carrier screening, or preventive genetic screening from individuals for whom genetic testing was performed between January 1, 2015, and June 30, 2023. Exposure DNA variants were classified into 1 of 5 categories: benign, likely benign, variant of uncertain significance (VUS), likely pathogenic, or pathogenic. Main Outcomes and Measures The main outcomes were accuracy of classifications, rates and directions of reclassifications, evidence contributing to reclassifications, and their impact across different clinical areas and REA groups. One-way analysis of variance followed by post hoc pairwise Tukey honest significant difference tests were used to analyze differences among means, and pairwise Pearson χ 2 tests with Bonferroni corrections were used to compare categorical variables among groups.

Results

The cohort comprised 3 272 035 individuals (median [range] age, 44 [0-89] years; 2 240 506 female [68.47%] and 1 030 729 male [31.50%]; 216 752 Black [6.62%]; 336 414 Hispanic [10.28%]; 1 804 273 White [55.14%]). Among 2 051 736 variants observed over 8 years in this cohort, 94 453 (4.60%) were reclassified. Some variants were reclassified more than once, resulting in 105 172 total reclassification events. The majority (64 752 events [61.65%]) were changes from VUS to either likely benign, benign, likely pathogenic, or pathogenic categories. An additional 37.66% of reclassifications (39 608 events) were gains in classification certainty to terminal categories (ie, likely benign to benign and likely pathogenic to pathogenic). Only a small fraction (663 events [0.63%]) moved toward less certainty, or very rarely (61 events [0.06%]) were classification reversals. When normalized by the number of individuals tested, VUS reclassification rates were higher among specific underrepresented REA populations (Ashkenazi Jewish, Asian, Black, Hispanic, Pacific Islander, and Sephardic Jewish). Approximately one-half of VUS reclassifications (37 074 of 64 840 events [57.18%]) resulted from improved use of data from computational modeling. Conclusions and Relevance In this cohort study of individuals undergoing genetic testing, the empirically estimated accuracy of pathogenic, likely pathogenic, benign, and likely benign classifications exceeded the certainty thresholds set by current VC guidelines, suggesting the need to reevaluate definitions of these classifications. The relative contribution of various strategies to resolve VUS, including emerging machine learning–based computational methods, RNA analysis, and cascade family testing, provides useful insights that can be applied toward further improving VC methods, reducing the rate of VUS, and generating more definitive results for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingGenetic Diseases, InbornHumansFemaleMaleCohort StudiesAdultGenetic VariationMiddle AgedAdolescentChildYoung Adult

Autor:innen und Institutionen

  • Labcorp Genetics Inc (formerly Invitae Corporation), San Francisco, California.
  • Invitae Corporation (now part of Labcorp Genetics), San Francisco, California.
  • Now with Midi Health, Los Altos Hills, California.
  • Now with GeneDx, Stamford, Connecticut.
  • Now with Illumina, San Diego, California.
  • Department of Pathology, Stanford University, Stanford, California.

Zitieren

APA

Kobayashi, Y., Chen, E., Facio, F. M., Metz, H., Poll, S. R., Swartzlander, D., Johnson, B., & Aradhya, S. (2024). Clinical Variant Reclassification in Hereditary Disease Genetic Testing. JAMA Network Open, 7(11), e2444526. https://doi.org/10.1001/jamanetworkopen.2024.44526

Vancouver

Kobayashi Y, Chen E, Facio FM, Metz H, Poll SR, Swartzlander D, et al. Clinical Variant Reclassification in Hereditary Disease Genetic Testing. JAMA Network Open. 2024;7(11):e2444526. doi:10.1001/jamanetworkopen.2024.44526

BibTeX
@article{Kobayashi2024,
  author = {Kobayashi, Yuya and Chen, Elaine and Facio, Flavia M and Metz, Hillery and Poll, Sarah R and Swartzlander, Dan and Johnson, Britt and Aradhya, Swaroop},
  title = {Clinical Variant Reclassification in Hereditary Disease Genetic Testing},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {11},
  pages = {e2444526},
  doi = {10.1001/jamanetworkopen.2024.44526}
}
Kostenlos starten →